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Abstract
Introduction: It is unclear whether the proportions of remission and the recurrence rates 
differ between endoscopic transsphenoidal surgery (TS) and microscopic TS in Cushing’s 
disease (CD); thus, we conducted a systematic review and meta-analysis to evaluate 
studies of endoscopic TS and microscopic TS.
Methods: We conducted a comprehensive search of PubMed to identify relevant studies. 
Remission and recurrence were used as outcome measures following surgical treatment 
of CD.
Results: A total of 24 cohort studies involving 1670 adult patients were included in the 
comparison. Among these studies, 702 patients across 9 studies underwent endoscopic 
TS, and 968 patients across 15 studies underwent microscopic TS. Similar baseline 
characteristics were observed in both groups. There was no significant difference in 
remission between the two groups: 79.7% (95% CI: 73.1–85.0%) in the endoscopic 
group and 76.9% (95% CI: 71.3–81.6%) in the microscopic group (P = 0.485). It appears 
that patients who underwent endoscopic surgery experience recurrence less often than 
patients who underwent microscopic surgery, with recurrence proportions of 11.0% 
and 15.9%, respectively (P = 0.134). However, if follow-up time is taken into account, 
both groups had a recurrence rate of approximately 4% per person per year (95% CI: 
3.1–5.4% and 3.6–5.1%, P = 0.651).
Conclusions: We found that remission proportion and recurrence rate were the same in 
patients who underwent endoscopic TS as in patients who underwent microscopic TS. 
The definition of diagnosis, remission and recurrence should always be considered in the 
studies assessing therapeutic efficacy in CD.
Introduction
Cushing’s disease (CD) is a subtype of pituitary adenoma 
with hypercortisolism and presents a particular challenge 
to neurosurgeons. Transsphenoidal surgery (TS) has long 
been the standard of care for patients with CD (1, 2, 3, 4). 
However, even under the most favorable circumstances, 
previous reports have found recurrence proportions of up 
to 10–20% after the first TS (5, 6, 7). Recurrent or residual 
CD is associated with a threefold to fivefold increase in 
mortality rate (8, 9, 10).
In recent decades, the application of endoscopes in 
the approach for treating pituitary adenomas has gained 
considerable popularity (11, 55, 56). The endoscopic 
technique provides a panoramic surgical view with 
increased illumination of the anatomic structures and 
allows for a close-up visual examination of the suspected 
tumor. Different optical angles can be used to make it 
possible to reach the suprasellar region as well as lateral 
extensions (12, 13). Owing to these advantages, increasing 
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numbers of neurosurgeons have started to adopt the 
endoscopic technique in recent years. Compared with 
microscopic surgery, endoscopic transsphenoidal tumor 
resection seems to lead to improved patient outcomes, 
especially in those patients with cavernous sinus invasion 
(14, 15, 16, 17, 18, 19, 20). In patients with CD, though a 
few studies do indicate a lower recurrence rate (15, 21, 22), 
it is still unclear whether the endoscopic technique has any 
advantages. Indeed, follow-up time in these studies was 
relatively short. It is unclear whether the proportions of 
remission and recurrence rates differ between endoscopic 
TS and microscopic TS.
The best way to compare clinical outcomes between 
endoscopic TS and microscopic TS is to execute a clinical 
trial (23), which is neither feasible nor practical due to 
limited sample size, variation in surgeons’ experience, 
institutional differences and ethical considerations. Thus, 
to gain more insight into the potential advantages of 
endoscopic TS for patients with CD, especially with respect 
to endocrine outcomes, we conducted a systematic review 
and meta-analysis to evaluate studies of endoscopic TS 
and microscopic TS.
Method
Study search strategy
We conducted a comprehensive search (‘Pituitary ACTH 
Hypersecretion/surgery’ (Mesh) or ‘CD surgery’) using 
PubMed to identify relevant studies without limitation 
on language. Reference lists from studies and systematic 
reviews identified electronically were manually searched 
to identify additional eligible studies. When more than 
one publication shared the same patient population, we 
included only the most recent report in the meta-analysis.
Inclusion and exclusion criteria
We identified eligible articles based on the following 
inclusion criteria: (1) publication date (later than 2005); (2) 
study design (cohort studies); (3) target adult population 
(microscopic TS or endoscopic TS of CD) and (4) sufficient 
published data to allow for the estimation of a rate with a 
95% confidence interval (CI).
To compare the differences between patients with 
endoscopic surgery and patients with microscopic surgery, 
several exclusion criteria were employed as follows: (1) 
studies without endocrinology outcome or follow-up 
data; (2) studies with a specific focus on a particular kind 
of tumor (e.g., macroadenomas or MRI-negative tumors); 
(3) studies that included children and/or teenagers; (4) 
studies with fewer than 20 CD patients and (5) studies 
that included both procedures or did not mention which 
procedure was used.
Studies with patients treated prior to 1990 were 
considered separately because the follow-up period was 
longer in these studies. We included these studies in this 
meta-analysis to examine the effect of long-term follow-up 
on recurrence.
Data extraction
The decision about whether a study should be included 
was made by the author (N Q). The results were reviewed 
by two senior physicians (M S and X S). The data extracted 
included the first author’s name and publication date, 
as well as patient age, gender composition, MRI feature, 
endocrine remission, follow-up time and recurrence.
The diagnosis of CD was established by Cushingoid 
symptoms; endogenous hypercortisolism; dynamic 
test, inferior petrosal sinus sampling and pituitary MRI 
in most studies. Positron emission tomography with 
18-fluorodeoxyglucose to localize a hypermetabolic 
focus within the sella was used in one study (22). The 
term ‘remission’ is defined by hypocortisolism with low 
serum cortisol (<5 μg/dL) and/or low urinary free cortisol 
(<20 mg per 24 h), and/or low cortisol (<1.8 mg/dL) level 
after 1 mg dexamethasone. Most of the studies also 
defined eucortisolism as remission (15, 17, 18, 25, 28, 
29, 30, 31, 32, 33, 34, 36, 37). Several studies also include 
the need for corticosteroid replacement and significant 
changes in clinical features as remission criteria (14, 25, 
30, 34, 35). The proportion of remission was calculated 
by dividing the number of patients with remission 
following surgery by the total number of patients. Half 
of the publications defined ‘recurrence’ as elevated 
cortisol serum level and/or elevated midnight salivary 
cortisol levels and/or elevated 24-h UFC levels associated 
with clinical symptoms of CD (16, 20, 26, 28, 29, 30, 
33, 38). The proportion of recurrence following surgery 
was calculated by dividing the number of patients with 
recurrence by the number of patients with remission. 
We also estimated the recurrence rate, which was the 
number of patients with recurrence following surgery 
divided by the follow-up time (in patient-years) for 
patients with remission.
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Statistical methods
Demographic characteristics (age, gender, tumor volume 
and cavernous sinus invasion) and outcome (remission 
proportion, recurrence proportion and recurrence rate) 
between endoscopic and microsurgical approaches were 
compared using ‘metaprop’ function in R. Whether random-
effects or fixed-effects should be used was decided by the 
I2  tests. ‘Forest’ function in R was used for the forest plot 
with subgroup analysis. The presence of heterogeneity across 
trials was evaluated, and a P value ≤0.05 was considered to be 
significant. Meta-regressions were performed with potential 
modifiers. The sensitivity analysis was also performed by 
removing a single study to determine the influence of that 
individual data set on the pooled proportions or rates. Funnel 
plots were also constructed to estimate the publication bias 
of the literature. All the statistical analyses were performed 
with R Studio, version 1.0.143.
Results
Study characteristics
A total of 1104 citations were identified by our search 
strategy. After a detailed evaluation of these articles, 
80 studies remained for assessment. After applying the 
selection criteria, 36 cohort studies involving 4326 
patients were identified and included in the meta-analysis 
(14, 15, 16, 17, 18, 19, 20, 21, 22, 24, 25, 26, 27, 28, 29, 
30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 
46, 47, 48, 49, 50). In these 36 studies, 2656 patients were 
included in 12 studies (39, 40, 41, 42, 43, 44, 45, 46, 47, 
48, 49, 50) with treatments prior to 1990 and long-term 
follow-up. Among the remaining 24 studies, 702 patients 
across nine studies underwent endoscopic TS (14, 15, 16, 
17, 18, 19, 20, 21, 22), and 968 patients across 15 studies 
underwent microscopic TS (24, 25, 26, 27, 28, 29, 30, 31, 
32, 33, 34, 35, 36, 37, 38). Baseline patient characteristics 
are summarized in Table 1.
Demographic characteristics
No study directly compared endoscopic and microsurgical 
approaches. Similar baseline characteristics were 
observed in both groups. The average patient age in 
the endoscopic group and the microscopic group was 
41.3 years and 41.4 years, respectively (P = 0.981). Females 
accounted for 79.5% (95% CI: 72.5–85.1%) of 702 
patients who underwent endoscopic surgery and 81.4% 
(95% CI: 78.2–84.1%) of 968 patients who underwent 
microsurgery (P = 0.583). Ta
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More patients in the microscopic group (62.8%) had 
micro-adenomas than did patients in the endoscopic group 
(53.1%, 95% CI: 56.1–69.1% and 46.4–59.7% respectively, 
P = 0.043). Conversely, more patients in the endoscopic 
group (30.6%) had macroadenomas than did patients 
in the microscopic group (22.0%, 95% CI: 23.5–38.7% 
and 17.0–27.9% respectively, P = 0.066). The proportion 
of MRI-negative tumors was nearly the same in both 
groups with 16.2% and 17.6% (95% CI: 10.3–24.4% and 
12.3–24.5%, P = 0.769), respectively. We determined that 
17.0% of patients treated endoscopically had cavernous 
sinus invasion compared with 11.9% of patients treated 
microsurgically (95% CI: 11.6–24.2% and 8.8–16.0%, 
P = 0.149), though most of the studies did not supply 
these data.
Outcome assessment
There was no significant difference in remission 
proportion between the two groups, as shown in Fig. 1: 
79.7% (95% CI: 73.1–85.0%) of the patients who 
underwent endoscopic TS were in remission compared 
to 76.9% (95% CI: 71.3–81.6%) in the microscopic TS 
group (P = 0.485) (Table 2). There was no difference in the 
remission of magnetic resonance image (MRI)-negative 
tumors or of macroadenomas (Figs  2 and 3, P = 0.229 
and P = 0.809, respectively); however, the proportion of 
remission in micro-adenomas was significantly higher in 
the endoscopic group (87.3%, 95% CI: 83.2–90.5%) than 
in the microscopic group (79.3%, 95% CI: 75.1–82.9%, 
P = 0.004, Fig. 4). 
It seems that fewer patients who underwent endoscopic 
surgery recurred than did patients who underwent 
microscopic surgery (Fig. 5), with recurrence proportions 
of 11.0% and 15.9% (95% CI: 7.6–15.7% and 11.5–21.7%, 
respectively; P = 0.134), respectively. However, if follow-up 
time is taken into account (36  months in endoscopic 
group and 53  months in microscopic group, P = 0.057), 
both groups had a recurrence rate of approximately 
4% per person per year (Fig.  6, 95% CI: 3.1–5.4% and 
3.6–5.1%, respectively; P = 0.651).
Figure 1
Forest plot of remission proportion in the two groups.
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To investigate the effect of follow-up time on 
recurrence, we also included studies that reported patients 
treated prior to 1990 and with long-term follow-up 
(98  months compared to 53  months, respectively; 
P = 0.010) (Table 3). There was no significant difference in 
remission between patients with long-term follow-up vs 
patients with relatively short follow-up times: 75.4% (95% 
CI: 73.1–85.0%) vs 76.9% (95% CI: 71.3–81.6%, P = 0.849), 
respectively. Recurrence rate was also comparable between 
these two groups with 2.7% (95% CI: 2.0–3.8%) and 4.0% 
(95% CI: 3.2–5.0%) per person per year, respectively.
Quality analysis
Heterogeneity across studies was observed in the 
proportions of remission (I2 = 67%, P < 0.01) and 
recurrence (I2 = 67%, P < 0.01). There was no indication of 
heterogeneity in the recurrence rate (I2 = 17%, P = 0.23). To 
investigate the source of the heterogeneity, we conducted 
meta-regressions with several potential modifiers: number 
of patients, publication year, location in which the study 
was conducted and remission criteria. Our meta-regression 
analysis revealed no significant effects on the proportion 
of remission for publication date (P = 0.362), study 
location (P = 0.142), number of enrolled cases (P = 0.142) 
or remission criteria (0.844). Publication date (P = 0.567), 
study location (P = 0.135) and number of enrolled cases 
(P = 0.440) did not contribute to the heterogeneity of 
recurrence proportion.
In the sensitivity analysis, a single study was removed 
to determine the influence of that individual data set 
on the pooled proportions or rates; the corresponding 
proportions and rates were not significantly altered, 
indicating that our results are statistically robust. Funnel 
plots were constructed to estimate the publication bias 
of the literature; the results suggest that any potential 
publication bias did not substantially influence the results 
of this meta-analysis.
Discussion
This systematic review and meta-analysis compares 
outcomes in endoscopic and microsurgical approaches for 
the treatment of ACTH-secreting pituitary adenomas. In 
our study, we found that basic characteristics of patients 
treated endoscopically were comparable to those of 
patients treated microscopically, except that more patients 
treated endoscopically had macroadenomas. Similar 
remission proportions were found for both endoscopic Ta
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Figure 3
Forest plot of remission proportion of macroadenomas in the two groups.
Figure 2
Forest plot of remission proportion of MRI-negative adenomas in the two groups.
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and microsurgical approaches, though remission criteria 
differed from study to study. Patients treated with the 
endoscopic approach for micro-adenomas were more likely 
to achieve remission than those treated microsurgically. 
Recurrence seemed to be lower among patients treated 
endoscopically; however, when follow-up time is taken 
into account, this advantage disappears.
Because most of the studies with endoscopy were 
performed in the latest 10–15  years. To eliminate the 
time as a confounding factor, we only included studies 
performed after 2005 (the oldest eligible publication 
on endoscopic TS is 2006). We only included studies 
with more than 20 patients because we believe surgical 
outcomes of CD are influenced by doctors’ experience. On 
the other hand, we also performed sensitive analysis, even 
studies with less 20 patients were included, the result did 
not change. Studies with patients treated prior to 1990 
were considered separately because the follow-up period 
was longer in these studies.
Endoscopic visualization provides a more panoramic 
view of the operative field, compared with the microscope, 
allowing for better viewing of the suprasellar region 
(51, 52). It is also possible to use instruments with a variety 
of angles to access lateral invasions of tumors (12, 13). 
Endoscopic surgery is an excellent approach for patients 
with CD, as the typically small size of the tumor requires 
higher magnification. Intrasellar illumination provided by 
the endoscope is extremely helpful in the intraoperative 
identification of abnormal tissue (19, 20, 22, 53). However, 
continuous adjustment of the endoscope is needed to 
determine target location within the surgical field, which 
may compromise maneuverability. Unlike endoscopic 
visualization, microsurgery offers a continuous view with 
a stereotactic display, which is familiar to the majority 
of surgeons and may allow for better control of bleeding 
in an open field. In recent years, some papers about 3D 
endoscopy for pituitary adenoma have been published 
(67, 68). This technique can combine depth perception in 
microscopy and wide-view in endoscopy. But no studies 
with 3D endoscopy were reported in patients with CD.
In the early days of endoscopic surgery, a large meta-
analysis by Ammirati and coworkers (54) concluded that 
endoscopic removal of pituitary adenoma does not seem 
to confer any benefits over microscopic technology in 
Figure 4
Forest plot of remission proportion of microadenomas in the two groups.
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the short term. However, recent meta-analyses showed 
that the endoscopic technique is associated with higher 
gross tumor removal (57) and modest increases of 
resection rates in residual or recurrent cases (58). In 
patients with functional pituitary adenomas (growth 
hormone-secreting adenoma), Phan and coworkers (59) 
concluded that clinical use of the endoscopic approach 
conferred potential benefits, including increased remission 
rates with non-invasive macroadenomas, but that overall 
endocrine remission is comparable. Chen and coworkers 
(60) also concluded that both approaches yielded similar 
rates of remission. However, a meta-analysis comparing 
outcomes from endoscopic TS and microscopic TS 
was lacking.
Our results support these findings. Overall remission, 
remission in macroadenomas, and remission in MRI-
negative CD showed no differences between groups. We 
also found that remission proportions for micro-adenomas 
were significantly higher in patients treated with the 
endoscopic approach compared to patients treated with 
the microsurgical approach. The superior intraoperative 
visualization afforded by the endoscopic approach may 
account for this finding. A much more unobstructed view 
of the operative field may facilitate resection of much of 
the tumor, especially the pseudocapsule (61, 62, 63).
Complete surgical resection may be difficult for 
tumors with cavernous sinus infiltration due to the risks 
of injury of carotid artery and cranial nerves (69,  70). 
However, given the low occurrence of tumors with 
cavernous infiltration in each study, as well as the fact that 
few studies reported the remission of invasive tumors, the 
comparison between patients treated with endoscopic TS 
and microscopic TS was impossible in our analysis.
Regarding postoperative complications, previous 
studies include thorough descriptions and analyses, most 
of which demonstrate that patients who underwent 
endoscopic surgery had comparable proportions of 
complications, including diabetes insipidus, CSF leakage, 
hypocortisolemia, hypothyroidism, hypogonadism and 
visual defects, compared to patients who underwent 
microscopic surgery (57, 58, 59, 60). In this meta-analysis, 
we did not include any of these complications. Proportions 
Figure 5
Forest plot of recurrence proportion in the two groups.
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of sinusitis and epistaxis were also comparable in previous 
reports (59, 64).
The definition of remission for CD varies over time 
and across studies. The remission of clinical symptoms, 
the need for glucocorticoid replacement, low or normal 
cortisol levels, normal 24-h urinary free cortisol levels, 
late-night salivary cortisol levels and cortisol after the 
dexamethasone suppression test all have been used in the 
literature (14, 15, 16, 17, 18, 19, 20, 21, 22, 24, 25, 26, 27, 
28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 
44, 45, 46, 47, 48, 49, 50). A combination of two or three 
of the criteria mentioned earlier was used as the remission 
Figure 6
Forest plot of recurrence rate in the two groups.
Table 3 Studies with patients earlier than 1990 and with long-term follow-up.
 
Study
 
Year
 
Place
 
Cases
Follow-up 
(months)
Overall 
remission (%)
Proportion of 
recurrence (%)
Recurrence rate 
(/person year)
Valassi et al. (39) 1982–2007 Boston, USA 620 47.4 477 (76.9%) 62 (13.0%) 3.3%
Lindsay et al. (40) 1982–2004 Bethesda, USA 418 125 331 (79.2%) 40 (12.1%) 1.2%
Kim et al. (41) 1984–2010 Seoul, Korea 54 104.6 38 (70.4%) 18 (47.4%) 5.4%
Ciric et al. (42) 1970–2010 Chicago, Illinois 136 68.4 93 (68.4%) 9 (9.7%) 1.7%
Hassan-Smith et al. (43) 1988–2009 Birmingham, UK 72 55.2 60 (83.3%) 8 (13.3%) 2.9%
Lambert et al. (44) 1980–2011 New York, USA 346 75.6 230 (66.5%) 73 (31.7%) 5.0%
Alexandraki et al. (45) 1969–2001 London, UK 131 180 86 (65.6%) 31 (36.0%) 2.4%
Costenaro et al. (46) 1989–2013 Porto Alegre, Brazil 103 73.2 84 (81.6%) 9 (10.7%) 1.8%
Aranda et al. (47) 1974–2011 Barcelona, Spain 41 168 32 (78.0%) 21 (65.6%) 4.7%
Yamada et al. (48) 1988–2014 Tokyo, Japan 230 72.5 198 (86.1%) 14 (7.1%) 1.2%
Chandler et al. (49) 1980–2012 Michigan, USA 275 80.4 219 (79.6%) 37 (16.9%) 2.5%
Bansal et al. (50) 1987–2015 Maharashtra, India 230 74 151 (65.7%) 48 (31.8%) 5.2%
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criteria in our study. Due to improvements in biochemical 
assays, a new consensus holds more stringent criteria for 
remission (65): ‘a postoperative cortisol value of <2 mg/dL 
predicts a higher chance of long-term remission after TS 
in CD; most patients with postoperative cortisol values of 
2–5 mg/dL a few days after TS will also be in remission’. We 
also performed a subgroup analysis between studies with 
strict criteria and studies with lenient criteria. It turns out 
that no difference in remission proportion was observed 
in the two subgroups.
There was significant heterogeneity in the outcomes. 
This heterogeneity is likely impacted by differences 
in surgical technique, surgeon, team and institution 
experience or outcome criteria. It is also likely that 
differences in study design and definition of the outcomes 
influence heterogeneity (66).
A significant weakness of our analysis is that most 
studies use a relatively short follow-up time in patients 
with endoscopic TS. To compare recurrence rate between 
the two surgical groups, we assumed that there was 
no effect of follow-up time on recurrence rate. Meta-
regression showed that the slope of recurrence rate by 
follow-up time was minus 0.002 (P = 0.529), a trend 
suggesting that as follow-up time increases, recurrence 
rate may decrease. We found no studies that directly 
compared endoscopic and microsurgical approaches. 
Randomized trials with experienced surgeons and trials 
with long-term follow-up are required to help bridge the 
current gaps in the literature.
Conclusion
We found that overall remission proportion was the same 
in CD patients who underwent endoscopic TS compared 
to patients who underwent microscopic TS. However, 
patients treated with the endoscopic approach for 
micro-adenomas were more likely to achieve remission 
than those treated microsurgically. Patients treated 
endoscopically were less likely to experience recurrence; 
however, when follow-up time is taken into account, 
this advantage disappears. The definition of diagnosis, 
remission and recurrence is very challenging and variable, 
which has always to be considered in the interpretation 
of results of studies assessing therapeutic efficacy in CD.
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